Cumberland Pharmaceuticals, Inc. 是一家專營製藥公司,專注於收購、開發和商業化品牌處方藥產品。公司總部位於田納西州納什維爾,目前聘有91名全職員工。该公司於2009年8月11日上市。公司致力於收購、開發和商業化品牌處方藥產品。其產品組合包括:Acetadote(乙醯半胱氨酸)注射劑,用於治療對乙醯氨基酚中毒;Caldolor(布洛芬)注射劑,用於治療疼痛和發燒;Kristalose(乳果糖)口服溶液,一種處方瀉藥,用於治療便秘;Sancuso(格拉司瓊)透皮貼片,用於預防接受某些類型化療的患者出現噁心和嘔吐;Vaprisol(考尼瓦普坦)注射劑,用於提高因等容量性和高容量性低鈉血症而住院患者的血清鈉水平;以及 Vibativ(替拉萬星)注射劑,用於治療某些嚴重細菌感染,包括醫院獲得性及呼吸機相關細菌性肺炎,以及複雜性皮膚和皮膚組織感染。
Based on comprehensive analyst evaluations, we have synthesized critical insights from expert assessments to outline a cautious outlook for CPIX. Analysts note deteriorating fundamentals and challenging market sentiment, indicating potential downside risks in the near term. Following this expert analysis, we adopt a bearish stance on this stock. Our conclusion: CPIX is a Sell candidate.
CPIX stock price ended at $3.59 on 星期四, after dropping 8.88%
On the latest trading day Feb 05, 2026, the stock price of CPIX fell by 8.88%, dropping from $3.86 to $3.59. During the session, the stock saw a volatility of 7.52%, with prices oscillating between a daily low of $3.59 and a high of $3.86. On the latest trading day, the trading volume for CPIX decreased by 777.6K shares, aligning with the declining prices, which may indicate weakening market confidence in the near term. In total, 194.0K shares were traded, with a market value of approximately $53.7M.